Sheila Gujrathi, M.D., is the former CEO of Gossamer Bio, Inc., where she made significant strides in developing innovative treatments in the biopharma space. With a background in medicine and law, she brings a unique perspective to the industry. Before...

Sheila Gujrathi, M.D., is the former CEO of Gossamer Bio, Inc., where she made significant strides in developing innovative treatments in the biopharma space. With a background in medicine and law, she brings a unique perspective to the industry. Before her time at Gossamer, Dr. Gujrathi served as Chief Medical Officer of Receptos, Inc., where she played a pivotal role until its acquisition by Celgene. She has an impressive educational pedigree with a M.D. from Northwestern University, alongside a B.S. in Biomedical Engineering. During her leadership at Gossamer, she transformed corporate strategies and achieved a remarkable corporate performance level of 105% while navigating the challenges of the COVID-19 pandemic. In 2020, she received nearly $7.2 million in compensation for her efforts, which included a significant bonus and accelerated stock vesting during her transition. Her insider trading activity peaked at a remarkable $94.52 million in November 2019, reflecting her vested interests in the company’s success. Sheila Gujrathi has served on various boards, lending her expertise, and remains influential in the biotech sector.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Gossamer Bio, Inc. CEOs

G

Sheila Gujrathi, M.D.

Ex-CEO of Gossamer Bio, Inc.

Education

M.D. from the University of Texas, Southwestern

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

CEO of Gossamer Bio, Inc. for

2 years 10 months (Jan 2018 - Nov 2020)

Previous Experience

Chief Operating Officer at Gossamer Bio, Inc.

Rivals

Competitors/colleagues of Sheila Gujrathi, M.D.

Holdings

See how much did Sheila Gujrathi, M.D. make over time.

At Gossamer Bio, Sheila Gujrathi held a substantial stake in the company. In November 2019, her net holdings were valued at $94.52 million, showcasing her strong financial commitment and confidence in the company’s future. Throughout 2020, her holdings fluctuated, as...

At Gossamer Bio, Sheila Gujrathi held a substantial stake in the company. In November 2019, her net holdings were valued at $94.52 million, showcasing her strong financial commitment and confidence in the company’s future. Throughout 2020, her holdings fluctuated, as the company navigated the challenges of the pandemic. By the end of 2020, her insider trading transactions showed a continued investment, with values dropping to around $47.66 million in October 2020. Her wealth was significantly tied to Gossamer’s performance, as observed with the fluctuations in market value of shares she owned. Now, her holdings are mostly liquidated into cash, reflecting a different phase in her career after her transition from CEO in 2020.

Insider Trading

See recent insider trades of Sheila Gujrathi, M.D..

JANX

2,500 shares

JANX

Jun 26, 2024

Received

GOSS

189,500 shares

GOSS

Feb 14, 2020

Received

GOSS

$167.98K

GOSS at $16.80/share

Sep 27, 2019

Purchase

Compensation History

See how much did Sheila Gujrathi, M.D. make over time.

Dr. Sheila Gujrathi's compensation for 2020 at Gossamer Bio totaled approximately $7.2 million, a substantial amount for a CEO navigating the challenges of the biotech industry. This total included $494,000 as her base salary, with an additional $276,676 earmarked as a prorated incentive bonus that recognized her performance despite the pandemic's impact. Additionally, she benefited from a considerable amount of stock options and vested stock, valued at about $2.8 million. Notably, her compensation structure was carefully devised to attract high-caliber talent, tying closely to both company performance and her strong leadership capabilities. Her previous compensation in 2019 was significantly lower, which demonstrates her increased value to the company after proving herself as a strategic leader.

Year

2020

Total Compensation

$4.17M

Salary

$494.00K

Board Justification

The compensation program is designed to attract, retain and motivate individuals with superior ability, experience and leadership capability to deliver on our annual and long-term business objectives necessary to create stockholder value.

Bonus

$276.68K

Board Justification

Prorated incentive bonus for 2020 paid upon the time of her transition in 2020.

Other

$642.03K

Board Justification

Includes $66,000 in accrued but unused payout of paid time off, continued payment of her base salary for 12 months per her transition agreement, and healthcare coverage at our expense in the amount of $4,033 in connection with her transition.

Restricted Stock

$2.76M(180K RSU)

Board Justification

Restricted stock units that vested upon her transition agreement, which included 18 months’ accelerated vesting of her outstanding restricted stock.

Performance Metrics

Corporate performance goals were set prior to the onset of the COVID pandemic and were not adjusted, with a corporate performance percentage of 105% achieved.

Other Gossamer Bio, Inc. CEOs

Here are other CEOs of Gossamer Bio, Inc.

Faheem Hasnain

Founder and CEO of Gossamer Bio, Inc.

November 2020 - Present